this matters because drug appears to be much more toxic than originally thought. serious enough to halt new study enrollments. lower dose might be ok but there are no guarantees.
Money definitely a worry especially now with extra time needed to sort this out. At 60-70M cash burn rate each quarter they'll need something lined up in a year. Chances are there will be secondary offering that will be highly dilutive.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.